MedPath

The Role of Synbiotics in Modulating Host Physiology Via the Gut Microbiome

Not Applicable
Completed
Conditions
Healthy
Interventions
Dietary Supplement: Synbiotic
Registration Number
NCT06480812
Lead Sponsor
Elizabeth Simpson
Brief Summary

The current study is a proof of concept mechanistic study that will utilise a combination of prebiotic and probiotic (synbiotic) supplements. The proposed study will improve our understanding of the molecular mechanisms linking nutrition to health outcomes that are mediated by the gut microbiome.

Detailed Description

The aim of this study is to generate high quality pilot data examining the role of a combination of pre and probiotic (synbiotic) supplementation in improving metabolic health (particularly systemic inflammation) and quality of life.

Specific Aim 1: To deliver a wealth of data, including effect sizes, on the physiological effects of synbiotic supplementation on the changes in the microbiome and metabolomic profile of an individual.

Specific Aim 2: To investigate potential mechanisms whereby the gut microbiome modulates crucial physiological parameters such as inflammatory markers and mental well-being measures.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Participant is willing and able to give informed consent for participation in the study
  • Participant eligibility includes those aged >18 years who have a body mass index (BMI) between 18.5 and 39.9 kg/m2
  • Have a smart phone in order to download apps on phone
Exclusion Criteria
  • Have any gastrointestinal condition or food intolerance which could impact ability to comply with the intervention (e.g. IBS, malabsorptive conditions such as IBD, coeliac)
  • Have lactose intolerance
  • Have diabetes mellitus or any condition with an inflammatory component such as asthma, psoriasis, arthritis etc.
  • Are currently taking fibre or probiotic supplements
  • Are taking any prescribed medication
  • Are currently following or anticipated to commence a specialised commercially available weight loss diet and/or program
  • Are pregnant or breast feeding
  • Currently have a diagnosed psychiatric illness
  • History or current neurological condition (e.g. epilepsy)
  • Have taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Synbiotic armSynbioticSynbiotic mixure (10g prebiotic fibre + 170ml kefir) will be randomly allocated to eligible participants in order to test specific effects of the synbiotic mixture on gut microbiome composition and metabolic markers.
ControlSynbioticIndividuals in the control arm will not be provided with the test supplement and asked to carry on with their usual diet and lifestyle.
Primary Outcome Measures
NameTimeMethod
Change in systemic inflammatory profile6 weeks

Change in circulating markers of systemic inflammation in serum samples collected pre and post the 6-week intervention period.

Secondary Outcome Measures
NameTimeMethod
Change in gut microbiome profile6 weeks

Change in gut microbiome profile, assessed using 16s RNA sequencing analysis of faecal samples provided pre and post the 6-week intervention period

Changes in short chain fatty acids (SCFAs)6 weeks

Change in serum SCFAs measured by mass spectrometry pre and post the 4-week intervention period

Mental Wellbeing as measured by validated questionnaires6 weeks

The Hospital Anxiety and Depression Survey (HADS) was used to assess subjective measures of anxiety and depression. The scores for each subscale (HADS-Anxiety (A) and HADS-Depression (D)) range from 0 to 21. The cut-off scores range from:

0-7: Normal (no significant symptoms) 8-10: Borderline or mild symptoms 11-21: Clinically significant anxiety or depression

Changes in skin microbiome profile6 weeks

Change in skin microbiome profile, assessed using 16s RNA sequencing analysis of faecal samples provided pre and post the 6-week intervention period

Trial Locations

Locations (1)

University of Nottingham

🇬🇧

Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath